Lexaria Bioscience Corp. (NASDAQ: LEXX) is aware of the need to continuously improve its understanding of the capabilities and potential applications of its patented DehydraTECH(TM) drug delivery technology. This informs its long-held commitment to its applied research and development (“R&D”) programs. “So far, the company’s research journey has involved a series of controlled and well-designed … Continue reading “NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Continues to Unlock Capabilities of Revolutionary DehydraTECH(TM) Platform”
Global drug delivery innovator Lexaria Bioscience is researching the ability of its patented DehydraTECH(TM) technology to improve the performance of a number of prescription drugs Lexaria is a world leader in the investigation of a DehydraTECH-processed cannabidiol (“CBD”) to potentially treat high blood pressure (hypertension), and study outcomes thus far have rendered positive results on … Continue reading “Lexaria Bioscience Corp. (NASDAQ: LEXX) Launches Fourth Human Study for Reducing Hypertension, Reports Positive Outcome of Third Human Study’s Data”
Lexaria expects to begin dosing this summer as part of a human nicotine study, NIC-H22-1, to compare DehydraTECH-nicotine pouch performance to that of existing leading brands such as ON! and Zyn So far, the company’s animal studies have evidenced that the technology delivers outstanding results, including faster delivery, an increase in the quantity of peak … Continue reading “Lexaria Bioscience Corp. (NASDAQ: LEXX) Advancing DehydraTECH-Nicotine Research to Support Safer, More Effective Oral Alternative to Harmful Pulmonary Administration Practices”
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced its receipt of its first-ever patent for the use of DehydraTECH technology in the enhanced delivery of antiviral drugs. According to the update, Lexaria has received notification from the United States Patent and Trademark Office that patent 11,311,559 for “Compositions and … Continue reading “NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Secures First-Ever Patent for DehydraTECH to Deliver Antiviral Drugs”
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that it has begun its multi-week human clinical hypertension study. The randomized, double blinded, placebo-controlled, cross-over study in 60 people, HYPER-H21-4, is the most comprehensive study ever undertaken by Lexaria. HYPER-H21-4 is designed to enhance Lexaria’s probability of success with its … Continue reading “NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Commences Its Most Comprehensive Study to Date”
Lexaria’s patented DehydraTECH(TM) technology has proven, in the NIC-A21-1 animal study, to be 10-20 times faster in reaching peak delivery of nicotine to the bloodstream than controls The company hopes to affirm this in the NIC-H22-1 human nicotine study as their DehydraTECH-nicotine pouch performance will be compared to existing leading brands currently sold in the … Continue reading “Lexaria Bioscience Corp. (NASDAQ: LEXX) Advances its Human Nicotine Study and Announces New Nicotine Formulation Creation and Evaluation Program with Altria”
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has released data from its HYPER-H21-3 human study. The company noted that data from its simulated pulmonary hypertension clinical study indicate positive safety and efficacy findings. Specifically, results show a tendency (p=0.1) during 15 minutes of simulated low levels of oxygen (hypoxia) for reduced pulmonary … Continue reading “NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Positive Results from Pulmonary Hypertension Clinical Study”
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced details of human nicotine study NIC-H22-1, which is expected to begin dosing this summer. According to the announcement, NIC-H22-1 is a minimum 36-person human pharmacokinetic (“pk”) randomized, double blinded, cross-over study to compare Lexaria’s DehydraTECH-nicotine pouch performance to that of existing … Continue reading “NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Issues Update on Human Nicotine Study NIC-H22-1”
Lexaria Bioscience, the global innovator behind DehydraTECH drug delivery technology, has continuously focused on research into its patented technology The company has conducted both in vitro testing and in vivo animal and human testing to evaluate the ability of DehydraTECH to improve the delivery of various APIs (active pharmaceutical ingredients) Lexaria has multiple other studies … Continue reading “Lexaria Bioscience Corp. (NASDAQ: LEXX): A Review of Its Research Developments”
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has entered agreements with Altria Client Services LLC. According to the announcement, the agreements call for Lexaria to provide specific DehydraTECH(TM) powder-based nicotine formulations for a fee; Altria in turn will evaluate the formulations. The new agreements will continue through March 31, 2023. Lexaria Bioscience’s … Continue reading “NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Beginning of New Nicotine Formulation Creation, Evaluation Program”
